Amphastar Pharmaceuticals (AMPH) Earnings Analysis

Amphastar Pharmaceuticals (AMPH) has no confirmed upcoming earnings date. Last quarter (2026-05-07) it missed with EPS 0.42 USD vs 0.7 USD est (-40%). It has beaten estimates in 2/5 recent quarters (40%). Trailing P/E 11.29.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does AMPH next report earnings?

No confirmed upcoming earnings date is currently scheduled for AMPH. This page updates as the calendar is published.

AMPH earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-070.42 USD0.7 USD-40%Miss
2026-02-260.73 USD0.903 USD-19.2%Miss
2025-11-060.93 USD0.77 USD+20.8%Beat
2025-08-070.85 USD0.71 USD+19.7%Beat
2025-02-270.92 USD1.01 USD-8.9%Miss

Beat rate: 2/5 (40%) over reported quarters with consensus data.

AMPH valuation and analyst view

Trailing P/E11.29
Trailing EPS1.748 USD
Price / book1.13
Dividend yield0.00%
Market cap0.85B
Analyst consensusHold (3 buy / 8 hold / 1 sell)
Avg price target20 USD

Related research pages

Frequently asked questions

When is Amphastar Pharmaceuticals (AMPH)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for AMPH. This page updates as the calendar is published.

Did AMPH beat earnings last quarter?

In its 2026-05-07 report, AMPH posted EPS of 0.42 USD versus a 0.7 USD estimate — a miss of 40%.

What is AMPH's earnings track record?

Over the last 5 reported quarters with consensus data, AMPH beat estimates 2 times (40%).

What is AMPH's current P/E ratio and EPS?

AMPH trades at a trailing P/E of 11.29 on trailing EPS of 1.7481355633025903 USD.

What do analysts rate AMPH?

Analyst consensus is "Hold" across 12 ratings (0 strong buy, 3 buy, 8 hold, 1 sell, 0 strong sell). Average 12-month price target: 20 USD.